Hannah Echols
| This email address is being protected from spambots. You need JavaScript enabled to view it.Public Relations Specialist
echolsh@uab.edu • (205) 704-2939Specific beats include: School of Nursing; School of Public Health; Division of Clinical Immunology and Rheumatology; Division of Endocrinology, Diabetes and Metabolism; Division of Gastroenterology and Hepatology; Division of Nephrology; Department of Genetics; Department of Pediatrics; Women's Health; Ophthalmology/UAB Callahan Eye Hospital ; Neurology; Neurosurgery
Since 1985, the Coronary Artery Risk Development in Young Adults study has examined the factors that contribute to the development of cardiovascular disease to better understand the natural history of cardiovascular disease over the adult life course.
TCE is a known environmental risk factor for parkinsonism. UAB researchers will evaluate whether T cell activation caused by TCE exposure leads to cognitive decline.
UAB Medicine has added the ExcelsiusGPS® by Globus Medical for minimally invasive spine surgeries.
The National Ataxia Foundation has named UAB a Center of Excellence. The designation is awarded to regional centers providing comprehensive care and services for individuals affected by ataxia and their families.
Jada King spent her childhood caring for her sister. Four years after her sister’s passing, King will graduate from the UAB School of Nursing and work with patients like her sister as a pediatric intensive care nurse.
$46 million awarded by NIH to UAB and partners allows researchers to continue following participants enrolled in the national Multicenter Osteoarthritis Study.
Published results from two UAB studies found the duration of intermittent hypoxemia events and the presence and persistence of a patent ductus arteriosus after birth are two novel risk factors of BPD-PH in preterm infants.
Despite fewer drivers on the roads and fewer injuries per accident, fatal crashes in Alabama increased by 26 percent over the three years from 2020 through 2022.
Cure HHT has named the HHT Clinic at UAB Hospital a Center of Excellence. Only hospitals equipped with the proper personnel, expertise, commitment and resources to provide comprehensive evaluation, treatment and education to individuals with HHT and their families receive this designation.
UAB was involved in clinical trials that led to an accelerated approval of the drug lecanemab, commercially known as Leqembi, in January 2023. A UAB Alzheimer’s expert discusses the therapy and what full approval means for the AD field.